An Open-Label, Randomized Trial of Intramuscular Olanzapine Versus Intramuscular Combination of Haloperidol and Lorazepam in the Treatment of Acute Agitation in Schizophrenia.

Trial Profile

An Open-Label, Randomized Trial of Intramuscular Olanzapine Versus Intramuscular Combination of Haloperidol and Lorazepam in the Treatment of Acute Agitation in Schizophrenia.

Completed
Phase of Trial: Phase III

Latest Information Update: 31 Oct 2012

At a glance

  • Drugs Olanzapine (Primary) ; Haloperidol; Lorazepam
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Oct 2012 Status changed from recruiting to completed.
    • 17 Oct 2012 Results presented at the 25th Annual Congress of the European College of Neuropsychopharmacology.
    • 14 Oct 2012 Primary endpoint 'Positive-and-Negative-Syndrome-Scale' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top